menu
    • menu

    Company profile for Can-Fite BioPharma

    NEW Drugs in Dev: 4
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the tr...
    Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Can-Fite BioPharmaIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    10 Bareket Street, Kiryat Matalon, PO Box 7537, Petah-Tikva, 4951778
    Telephone
    Telephone
    972 3 924 1114
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.canfite.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/canfitepharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite Advances Pancreatic Cancer Drug Study
    Can-Fite Advances Pancreatic Cancer Drug Study

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293853/0/en/following-positive-phase-2a-pancreatic-cancer-data-can-fite-advances-namodenoson-into-phase-2b-combination-study-with-immunotherapy.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Can-Fite's Namodenoson Shows Positive Phase 2A Results
    Can-Fite's Namodenoson Shows Positive Phase 2A Results

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284876/0/en/can-fite-reports-positive-phase-2a-data-with-namodenoson-in-pancreatic-cancer-35-of-patients-remain-on-therapy-including-one-beyond-16-months.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Vetbiolix Completes Ph2 OA Dog Study Piclidenoson Data Q3 2026
    Vetbiolix Completes Ph2 OA Dog Study Piclidenoson Data Q3 2026

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264512/0/en/Can-Fite-s-Partner-Vetbiolix-Completes-Enrollment-in-Phase-2-Osteoarthritis-Study-in-Dogs-Treated-with-Piclidenoson-Data-Expected-in-Q3-2026.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Can-Fite Reports 2025 Financial Results, Phase 2a Cancer Data
    Can-Fite Reports 2025 Financial Results, Phase 2a Cancer Data

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263128/0/en/Can-Fite-Reports-2025-Financial-Results-and-Ongoing-Clinical-Progress-Highlighting-Positive-Data-in-Phase-2a-Pancreatic-cancer-and-9-Years-Cancer-Free-Survival-in-Liver-Cancer-Pati.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use
    Can-Fite Secures Israeli Patent for Namodenoson Anti-Obesity Use

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257054/0/en/Can-Fite-Expands-Namodenoson-anti-Obesity-Franchise-with-Israeli-Patent-Allowance.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Can-Fite Exercises Warrants, Generating $4.0M In Gross Proceeds
    Can-Fite Exercises Warrants, Generating $4.0M In Gross Proceeds

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249502/0/en/Can-Fite-Announces-Exercise-of-Warrants-for-Approximately-4-0-Million-in-Gross-Proceeds.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search